Annual EBITDA
-$269.02 M
-$25.64 M-10.54%
December 31, 2022
Summary
- As of February 10, 2025, RETA annual EBITDA is -$269.02 million, with the most recent change of -$25.64 million (-10.54%) on December 31, 2022.
- During the last 3 years, RETA annual EBITDA has risen by +$9.01 million (+3.24%).
Performance
RETA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly EBITDA
$201.26 M
+$306.08 M+292.02%
June 30, 2023
Summary
- As of February 10, 2025, RETA quarterly EBITDA is $201.26 million, with the most recent change of +$306.08 million (+292.02%) on June 30, 2023.
- Over the past year, RETA quarterly EBITDA has increased by +$264.27 million (+419.44%).
Performance
RETA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBITDA
-$45.94 M
+$264.27 M+85.19%
June 30, 2023
Summary
- As of February 10, 2025, RETA TTM EBITDA is -$45.94 million, with the most recent change of +$264.27 million (+85.19%) on June 30, 2023.
- Over the past year, RETA TTM EBITDA has increased by +$209.66 million (+82.03%).
Performance
RETA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RETA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.5% | +419.4% | +82.0% |
| 3 y3 years | +3.2% | +430.0% | +86.7% |
| 5 y5 years | -487.7% | +840.0% | +83.5% |
RETA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | +10.5% | at low | at high | -152.1% | at high | +575.3% |
| 5 y | 5-year | +15.8% | +3.3% | at high | -190.8% | at high | +687.9% |
| alltime | all time | -4483.7% | +3.3% | at high | -190.8% | -2998.1% | +687.9% |
Reata Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | $201.26 M(-292.0%) | -$45.94 M(-85.2%) |
| Mar 2023 | - | -$104.81 M(+41.0%) | -$310.20 M(+15.3%) |
| Dec 2022 | -$269.02 M(+10.5%) | -$74.32 M(+9.2%) | -$269.02 M(+1.2%) |
| Sep 2022 | - | -$68.07 M(+8.0%) | -$265.93 M(+4.0%) |
| Jun 2022 | - | -$63.01 M(-1.0%) | -$255.60 M(+1.2%) |
| Mar 2022 | - | -$63.63 M(-10.7%) | -$252.46 M(+3.7%) |
| Dec 2021 | -$243.38 M(+4.8%) | -$71.23 M(+23.4%) | -$243.38 M(+8.0%) |
| Sep 2021 | - | -$57.73 M(-3.6%) | -$225.28 M(+2.1%) |
| Jun 2021 | - | -$59.86 M(+9.7%) | -$220.72 M(-0.5%) |
| Mar 2021 | - | -$54.56 M(+2.7%) | -$221.85 M(-4.5%) |
| Dec 2020 | -$232.32 M(-16.4%) | -$53.12 M(-0.1%) | -$232.32 M(-35.8%) |
| Sep 2020 | - | -$53.18 M(-12.8%) | -$361.92 M(+4.7%) |
| Jun 2020 | - | -$60.99 M(-6.2%) | -$345.76 M(+9.3%) |
| Mar 2020 | - | -$65.03 M(-64.4%) | -$316.48 M(+13.8%) |
| Dec 2019 | -$278.03 M(+276.2%) | -$182.72 M(+393.7%) | -$278.03 M(+134.9%) |
| Sep 2019 | - | -$37.01 M(+16.7%) | -$118.36 M(+7.9%) |
| Jun 2019 | - | -$31.71 M(+19.3%) | -$109.71 M(+4.3%) |
| Mar 2019 | - | -$26.59 M(+15.3%) | -$105.19 M(+42.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$73.91 M(+61.5%) | -$23.05 M(-18.7%) | -$73.92 M(+10.4%) |
| Sep 2018 | - | -$28.36 M(+4.3%) | -$66.94 M(+33.1%) |
| Jun 2018 | - | -$27.20 M(-679.6%) | -$50.31 M(+47.4%) |
| Mar 2018 | - | $4.69 M(-129.2%) | -$34.12 M(-25.5%) |
| Dec 2017 | -$45.78 M(+664.7%) | -$16.08 M(+37.1%) | -$45.78 M(+35.9%) |
| Sep 2017 | - | -$11.72 M(+6.5%) | -$33.69 M(+48.5%) |
| Jun 2017 | - | -$11.01 M(+58.2%) | -$22.69 M(+75.9%) |
| Mar 2017 | - | -$6.96 M(+74.5%) | -$12.90 M(+115.5%) |
| Dec 2016 | -$5.99 M(-503.1%) | -$3.99 M(+449.6%) | -$5.99 M(+161.9%) |
| Sep 2016 | - | -$726.00 K(-40.4%) | -$2.29 M(+287.5%) |
| Jun 2016 | - | -$1.22 M(+2242.3%) | -$590.00 K(+821.9%) |
| Mar 2016 | - | -$52.00 K(-82.1%) | -$64.00 K(-104.3%) |
| Dec 2015 | $1.49 M(-75.8%) | -$290.00 K(-129.9%) | $1.49 M(-6.3%) |
| Sep 2015 | - | $970.00 K(-240.2%) | $1.58 M(+157.7%) |
| Jun 2015 | - | -$692.00 K(-146.2%) | $615.00 K(-52.9%) |
| Mar 2015 | - | $1.50 M(-887.9%) | $1.31 M(-787.9%) |
| Dec 2014 | $6.14 M(-182.3%) | -$190.00 K | -$190.00 K |
| Dec 2013 | -$7.46 M | - | - |
FAQ
- What is Reata Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Reata Pharmaceuticals?
- What is Reata Pharmaceuticals annual EBITDA year-on-year change?
- What is Reata Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Reata Pharmaceuticals?
- What is Reata Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Reata Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Reata Pharmaceuticals?
- What is Reata Pharmaceuticals TTM EBITDA year-on-year change?
What is Reata Pharmaceuticals annual EBITDA?
The current annual EBITDA of RETA is -$269.02 M
What is the all time high annual EBITDA for Reata Pharmaceuticals?
Reata Pharmaceuticals all-time high annual EBITDA is $6.14 M
What is Reata Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, RETA annual EBITDA has changed by -$25.64 M (-10.54%)
What is Reata Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of RETA is $201.26 M
What is the all time high quarterly EBITDA for Reata Pharmaceuticals?
Reata Pharmaceuticals all-time high quarterly EBITDA is $201.26 M
What is Reata Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, RETA quarterly EBITDA has changed by +$264.27 M (+419.44%)
What is Reata Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of RETA is -$45.94 M
What is the all time high TTM EBITDA for Reata Pharmaceuticals?
Reata Pharmaceuticals all-time high TTM EBITDA is $1.58 M
What is Reata Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, RETA TTM EBITDA has changed by +$209.66 M (+82.03%)